Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
European Journal of Nuclear Medicine and Molecular Imaging
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 10/2016

28.04.2016 | Review Article

Radium-223 dichloride in clinical practice: a review

verfasst von: Luigia Florimonte, Luca Dellavedova, Lorenzo Stefano Maffioli

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 10/2016

Einloggen, um Zugang zu erhalten

Abstract

The onset of skeletal metastases is typical of advanced-stage prostate cancer and requires a multidisciplinary approach to alleviate bone pain and try to delay disease progression. The current therapeutic armamentarium includes conventional analgesics, chemotherapeutic agents, immunotherapy, androgen-deprivation therapy, osteoclast inhibitors (bisphosphonates, denosumab), surgical interventions, external-beam radiotherapy and radionuclide metabolic therapy. Many studies in recent decades have demonstrated the efficacy of various radiopharmaceuticals, including strontium-89 and samarium-153, for palliation of pain from diffuse skeletal metastases, but no significant benefit in terms of disease progression and overall survival has been shown. The therapeutic landscape of metastatic skeletal cancer significantly changed after the introduction of radium-223, the first bone-homing radiopharmaceutical with disease-modifying properties. In this paper we extensively review the literature on the use of radium-223 dichloride in metastatic castration-resistant prostate cancer.
Literatur
1.
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRefPubMed
2.
Miller DC, Hafez KS, Stewart A, et al. Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base. Cancer. 2003;98:1169–78.CrossRefPubMed
3.
4.
5.
Lipton A, Uzzo R, Amato RJ, et al. The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. J Natl Compr Canc Netw. 2009;7 Suppl 7:S1–30.PubMedPubMedCentral
6.
Henriksen G, Breistol K, Bruland OS, Fodstad O, Larsen RH. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res. 2002;62:3120–5.PubMed
7.
8.
Ibrahim T, Flamini E, Mercatali L, et al. Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer. 2010;116:1406–18.CrossRefPubMed
9.
Blacksburg SR, Witten MR, Haas JA. Integrating bone targeting radiopharmaceuticals into the management of patients with castrate-resistant prostate cancer with symptomatic bone metastases. Curr Treat Options Oncol. 2015;16:325.CrossRefPubMed
10.
Bienz M, Saad F. Management of bone metastases in prostate cancer: a review. Curr Opin Support Palliat Care. 2015;9:261–7.CrossRefPubMed
11.
Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458–68.CrossRefPubMed
12.
13.
Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009;27(10):1564–71.CrossRefPubMed
14.
Smith MR, Egerdie B, Hernandez TN, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8):745–55.CrossRefPubMedPubMedCentral
15.
Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813–22.CrossRefPubMedPubMedCentral
16.
Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012;379(9810):39–46.CrossRefPubMed
17.
Rubini G, Nicoletti A, Rubini D, Asabella AN. Radiometabolic treatment of bone-metastasizing cancer: from 186rhenium to 223radium. Cancer Biother Radiopharm. 2014;29(1):1–11.CrossRefPubMed
18.
Ariel IM, Hassouna H. Carcinoma of the prostate: the treatment of bone metastases by radioactive phosphorus. Int Surg. 1985;70:63–6.PubMed
19.
Lewington VJ. Bone-seeking radionuclides for therapy. J Nucl Med. 2005;46:38S–47.
20.
Den RB, Doyle LA, Knudsen E. Practical guide to the use of radium-223 dichloride. Can J Urol. 2014;21 Suppl 1:70–6.PubMed
21.
Porter AT, McEwan AJ, Powe JE, et al. Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25(5):805–13.CrossRefPubMed
22.
Mertens WC, Stitt L, Porter AT. Strontium-89 therapy and relief of pain in patients with prostatic carcinoma metastatic to bone: a dose response relationship? Am J Clin Oncol. 1993;16(3):238–42.
23.
Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol. 2005;6(6):392–400.CrossRefPubMed
24.
Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized phase II trial. Lancet. 2001;357(9253):336–41.CrossRefPubMed
25.
Palmedo H, Manka-Waluch A, Albers P, et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol. 2003;21(15):2869–75.CrossRefPubMed
26.
Turner JH, Claringbold PG, Hetherington EL, et al. A phase I study of Samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases. J Clin Oncol. 1989;7(12):1926–31.PubMed
27.
Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol. 1998;16(4):1574–81.PubMed
28.
Tian JH, Zhang JM, Hou QT, et al. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Eur J Nucl Med. 1999;26(1):2–7.CrossRefPubMed
29.
Sartor O, Reid RH, Hoskin PJ, et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004;63(5):940–5.CrossRefPubMed
30.
Fizazi K, Beuzeboc P, Lumbroso J, et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol. 2009;27(15):2429–35.CrossRefPubMed
31.
Ando A, Ando I, Tonami N, et al. 177Lu-EDTMP: a potential therapeutic bone agent. Nucl Med Commun. 1998;19(6):587–91.CrossRefPubMed
32.
Chakraborty S, Das T, Banerjee S, et al. 177Lu-EDTMP: a viable bone pain palliative in skeletal metastasis. Cancer Biother Radiopharm. 2008;23(2):202–13.CrossRefPubMed
33.
Agarwal KK, Singla S, Arora G, et al. (177)Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study. Eur J Nucl Med Mol Imaging. 2015;42(1):79–88.CrossRefPubMed
34.
Thapa P, Nikam D, Das T, et al. Clinical efficacy and safety comparison of 177Lu-EDTMP with 153Sm-EDTMP on an equidose basis in patients with painful skeletal metastases. J Nucl Med. 2015;56(10):1513–9.CrossRefPubMed
35.
Guerra Liberal FD, Tavares AA, Tavares JM. Comparative analysis of 11 different radioisotopes for palliative treatment of bone metastases by computational methods. Med Phys. 2014;41(11):114101.CrossRefPubMed
36.
Hirao M, Hashimoto J, Yamasaki N, et al. Oxygen tension is an important mediator of the transformation of osteoblasts to osteocytes. J Bone Miner Metab. 2007;25:266–76.CrossRefPubMed
37.
Barensden GW. Responses of cultured cells, tumours and normal tissues to radiations of different linear energy transfer. In: Ebert M, Howard A, editors. Current topics in radiation research, vol. IV. Amsterdam, Netherlands: North-Holland; 1968. p. 293–356.
38.
Tinganelli W, Ma NY, Von Neubeck C, et al. Influence of acute hypoxia and radiation quality on cell survival. J Radiat Res. 2013;54 Suppl 1:i23–30.CrossRefPubMedPubMedCentral
39.
Seidl C. Radioimmunotherapy with α-particle-emitting radionuclides. Immunotherapy. 2014;6(4):431–58.CrossRefPubMed
40.
Miller BW, Frost SH, Frayo SL, et al. Quantitative single-particle digital autoradiography with α-particle emitters for targeted radionuclide therapy using the iQID camera. Med Phys. 2015;42(7):4094–105.CrossRefPubMedPubMedCentral
41.
42.
43.
44.
Bruland OS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res. 2006;12:6250s–57s.CrossRefPubMed
45.
Wieder HA, Lassmann M, Allen-Auerbach MS, et al. Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters. World J Radiol. 2014;6(7):480–5.CrossRefPubMedPubMedCentral
46.
Gholami Y, Zhu X, Fulton R, et al. Stochastic simulation of radium-223 dichloride therapy at the sub-cellular level. Phys Med Biol. 2015;60:6087–96.CrossRefPubMed
47.
Carrasquillo JA, O'Donoghue JA, Pandit-Taskar N, et al. Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40(9):1384–93.CrossRefPubMed
48.
Lassmann M, Nosske D. Dosimetry of 223Ra-chloride: dose to normal organs and tissues. Eur J Nucl Med Mol Imaging. 2013;40:207–12.CrossRefPubMed
49.
Nilsson S, Larsen RH, Foss SD, et al. First clinical experience with α-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11(12):4451–9.CrossRefPubMed
50.
Nilsson S, Franzen L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007;8:587–94.CrossRefPubMed
51.
52.
53.
Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.CrossRefPubMed
54.
Dauer LT, Williamson MJ, Humm J, et al. Radiation safety considerations for the use of 223RaCl2 DE in men with castration-resistant prostate cancer. Health Phys. 2014;106(4):494–504.CrossRefPubMed
55.
Nilsson S, Strang P, Aksnes AK, et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer. 2012;48:678–86.CrossRefPubMed
56.
Parker CC, Pascoe S, Chodacki A, et al. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol. 2013;63:189–97.CrossRefPubMed
57.
Nilsson S, Franzén L, Parker C, et al. Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. Clin Genitourin Cancer. 2013;11(1):20–6.CrossRefPubMed
58.
Sartor O, Coleman R, Nilsson S, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014;15:738–46.CrossRefPubMed
59.
Nilsson S, Sartor O, Bruland OS, et al. Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases [abstract]. J Clin Oncol. 2013;19 Suppl 6:5038.
60.
Nilsson S, Tomblyn M, Cislo P, et al. Patient-reported quality of life (QOL) analysis of radium-223 dichloride (Ra-223) evaluating pain relief from the phase 3 ALSYMPCA study [abstract]. J Clin Oncol. 2014;32(5s):5069.
61.
Hoskin P, Sartor O, O'Sullivan JM, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15(12):1397–406.CrossRefPubMed
62.
Shirley M, McCormack PL. Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases. Drugs. 2014;74:579–86.CrossRefPubMed
63.
Ryan CJ, Saylor PJ, Everly JJ, et al. Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data. The Oncologist. 2014;19:1012–8.CrossRefPubMedPubMedCentral
64.
Herranz UA, Fernandez Calvo O, Afonso FJ, et al. Radium-223 dichloride: a new paradigm in the treatment of prostate cancer. Expert Rev Anticancer Ther. 2015;15(3):339–48.CrossRef
65.
McGann S, Horton ER. Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases. Ann Pharmacother. 2015;49(4):469–76.CrossRefPubMed
66.
Turner PG, O’Sullivan JM. 223Ra and other bone-targeting radiopharmaceuticals—the translation of radiation biology into clinical practice. Br J Radiol. 2015;88:20140752.CrossRefPubMedPubMedCentral
67.
Chalhoub E, Chalouhy C, Sartor O. Treatment of skeletal metastases with 223Ra-chloride. Clin Transl Imaging. 2015;3:159–65.CrossRef
68.
Pandit-Taskar N, Larson SM, Carrasquillo JA. Bone-seeking radiopharmaceuticals for treatment of osseous metastases, part 1: a therapy with 223Ra-dichloride. J Nucl Med. 2014;55:268–74.CrossRefPubMed
69.
Gartrell BA, Saad F. Pathologic fractures in patients with metastatic prostate cancer. Curr Opin Urol. 2014;24:595–600.CrossRefPubMed
70.
Graff JN, Beer TM. Pharmacotherapeutic management of metastatic, castration-resistant prostate cancer in the elderly: focus on non-chemotherapy agents. Drugs Aging. 2014;31:873–82.CrossRefPubMedPubMedCentral
71.
George D, Moul JW. Emerging treatment options for patients with castration-resistant prostate cancer. Prostate. 2012;72:338–49.CrossRefPubMed
72.
Parker C, Gillessen S, Heidenreich A, et al. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v69–77.
73.
74.
75.
Mukherji D, El Dika I, Temraz S, et al. Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer: role of radium-223. Ther Clin Risk Manag. 2014;10:373–80.CrossRefPubMedPubMedCentral
76.
Gernone A, Bordonaro S, Tralongo P. Optimal sequence of bone target drugs in metastatic prostatic cancer. Expert Rev Anticancer Ther. 2015;15(8):923–9.CrossRefPubMed
77.
Borsò E, Boni G, Galli L, et al. Radium-223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancer. Future Oncol. 2015;11(2):323–31.CrossRefPubMed
78.
Todenhöfer T, Stenzl A, Hofbauer LC, et al. Targeting bone metabolism in patients with advanced prostate cancer: current options and controversies. Int J Endocrinol. 2015;2015:838202CrossRefPubMedPubMedCentral
79.
80.
Dreicer R. How to approach sequencing therapy in patients with metastatic castration resistant prostate cancer. Can J Urol. 2014;21 Suppl 1:93–7.PubMed
81.
Sciuto R, Maini CL, Tofani A, et al. Radiosensitization with low dose carboplatin enhances pain palliation in radioisotope therapy with strontium-89. Nucl Med Commun. 1996;17(9):799–804.CrossRefPubMed
82.
Sciuto R, Festa A, Rea S, et al. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med. 2002;43(1):79–86.PubMed
83.
Ricci S, Boni G, Pastina I, et al. Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging. 2007;34(7):1023–30.CrossRefPubMed
84.
Borsò E, Boni G, Pastina I, et al. Safety and antitumor efficacy of 153Sm-EDTMP and docetaxel administered sequentially to patients with metastatic castration-resistant prostate cancer. Nucl Med Commun. 2014;35(1):88–94.CrossRefPubMed
85.
Rose JN, Crook JM. The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancer. Ther Adv Urol. 2015;7(3):135–45.CrossRefPubMedPubMedCentral
86.
Basch E, Loblaw EA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2014;32:3436–48.CrossRefPubMedPubMedCentral
87.
88.
89.
Morris MJ, Higano C, Scher HI, et al. Safety of radium-223 dichloride with docetaxel in patients with bone metastases from castration-resistant prostate cancer: a phase 1/2a clinical trial. Ann Oncol. 2014;25 Suppl 4:iv255–79.
90.
Finkelstein SE, Michalski JM, O’Sullivan JM, et al. EBRT use and safety with radium-223 dichloride in patients with CRPC and symptomatic bone metastases from the ALSYMPCA trial [abstract]. J Clin Oncol. 2015;33(7):182.
91.
Roach 3rd M. Radium-223 vs. EBRT for multiple painful bone metastases: is less more? Oncology (Williston Park). 2014;28(4):297–8.
92.
Jayasekera J, Onukwugha E, Bikov K, et al. The economic burden of skeletal-related events among elderly men with metastatic prostate cancer. Pharmacoeconomics. 2014;32:173–91.CrossRefPubMed
93.
Yong C, Onukwugha E, Mullins CD. Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer. Curr Opin Oncol. 2014;26:274–83.CrossRefPubMed
94.
Pani L. Riclassificazione del medicinale per uso umano «Xofigo», ai sensi dell’articolo 8, comma 10, della legge 24 dicembre 1993, n. 537. (Determina n. 576/2015). Gazzetta Ufficiale della Repubblica Italiana. General Series 2015, no. 121.
95.
96.
Guirgis HM. Novel methodology for cost evaluation of anticancer drugs in castrate-resistant prostate cancer [abstract]. J Clin Oncol. 2013;31 Suppl 6:200.
97.
Renzulli JF 2nd, Collins J, Mega A. Radium-223 dichloride: illustrating the benefits of a multidisciplinary approach for patients with metastatic castration-resistant prostate cancer. J Multidiscip Healthc. 2015;8:279–86.CrossRefPubMedPubMedCentral
98.
Shore ND. Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist’s perspective. Urology. 2015;85(4):717–24.CrossRefPubMed
99.
Takalkar A, Adams S, Subbiah V. Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone. Exp Hematol Oncol. 2014;3:23.CrossRefPubMedPubMedCentral
100.
Coleman R, Ak A, Naume B, et al. A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease. Breast Cancer Res Treat. 2014;145:411–8.CrossRefPubMedPubMedCentral
101.
102.
Chittenden SJ, Hindorf C, Parker CC, et al. A phase 1, open-label study of the biodistribution, pharmacokinetics and dosimetry of radium-223 dichloride (223Ra dichloride) in patients with hormone refractory prostate cancer and skeletal metastases. J Nucl Med. 2015;56(9):1304–9.CrossRefPubMed
103.
Jadvar H, Challa S, Quinn D, et al. One-year postapproval clinical experience with radium-223 dichloride in patients with metastatic castrate-resistant prostate cancer. Cancer Biother Radiopharm. 2015;30(5):195–9.
104.
Hindorf C, Chittenden S, Aksnes AK, et al. Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases. Nucl Med Commun. 2012;33(7):726–32.CrossRefPubMed
105.
Pacilio M, Ventroni G, De Vincentis G, et al. Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting 223Ra-dichloride. Eur J Nucl Med Mol Imaging. 2016;43:21–33.CrossRefPubMed
106.
Follacchio GA, Frantellizzi V, Pellegrini R, et al. Feasibility of 223Ra quantitative imaging for lesion dosimetry [abstract]. Eur J Nucl Med Mol Imaging. 2015;42(1 Suppl):OP236.
107.
Murray I, Chittenden SJ, Parker CC, et al. The potential of F-18 fluoride PET as a surrogate for radium-223 chloride lesion dosimetry in hormone refractory prostate cancer patients [abstract]. Eur J Nucl Med Mol Imaging. 2015;42(1 Suppl):OP235.
108.
Etchebehere EC, Araujo JC, Fox PS, et al. Prognostic factors in patients treated with 223Ra: the role of skeletal tumor burden on baseline 18F-fluoride PET/CT in predicting overall survival. J Nucl Med. 2015;56(8):1177–84.CrossRefPubMed
109.
Cook Jr G, Parker C, Chua S, et al. 18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin). EJNMMI Res. 2011;1(1):4.CrossRefPubMedPubMedCentral
110.
Miyazaki KS, Kuang Y, Kwee SA. Changes in skeletal tumor activity on (18)F-choline PET/CT in patients receiving (223)radium radionuclide therapy for metastatic prostate cancer. Nucl Med Mol Imaging. 2015;49(2):160–4.CrossRefPubMedPubMedCentral
111.
Sakretz M, Kurth J, Schwarzenböck SM, et al. Automatic bone scan index for therapy response assessment of radium-223-dichloride (Ra-223) therapy in advanced prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(1 Suppl):P748.
112.
Yu EY, Duan F, Muzi M, et al. Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687. J Nucl Med. 2015;56(3):354–60.CrossRefPubMedPubMedCentral
Metadaten
Titel
Radium-223 dichloride in clinical practice: a review
verfasst von
Luigia Florimonte
Luca Dellavedova
Lorenzo Stefano Maffioli
Publikationsdatum
28.04.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 10/2016
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-016-3386-5

Weitere Artikel der Ausgabe 10/2016

European Journal of Nuclear Medicine and Molecular Imaging 10/2016 Zur Ausgabe

Original Article

PET/CT comparing 68Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma

Editorial

PET/CT is a cost-effective tool against cancer: synergy supersedes singularity

Original Article

Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results

Original Article

[68Ga]DOTATATE PET/MRI and [18F]FDG PET/CT are complementary and superior to diffusion-weighted MR imaging for radioactive-iodine-refractory differentiated thyroid cancer

Original Article

 PET/MRI in pancreatic and periampullary cancer: correlating diffusion-weighted imaging, MR spectroscopy and glucose metabolic activity with clinical stage and prognosis

Image of the Month

18F-FDG hepatic superscan caused by a non-germinal center subtype of diffuse large B-cell lymphoma